EPIDEMIOLOGIC ASSESSMENT OF RISK FACTORS FOR DUAL DIAGNOSIS OF B-CELL AND T-CELL LYMPHOMAS

C.A. HUMMEL, S.S. KHAZNADAR, Z.E. HUNZEKER, J.W. HILL, K. MURPHY, A.A. AYERS, J. HENDERSON, T.S. ZUNIGA, C.R. FLOWERS, M. HAMILTON, M. GREEN, F. VEGA, A.C. LIONEL, D. CHIHARA

 

INTRODUCTION

- Epidemiologic studies demonstrate a nearly fivefold increased bidirectional risk between B-cell lymphomas (BCL) and T-cell lymphomas (TCL)

- The biologic mechanisms and shared risk factors underlying dual BCL/TCL diagnoses remain incompletely understood

- Comprehensive characterization of patients with dual diagnoses may provide insight into common mechanisms of lymphomagenesis

 

METHOD

- Study design: Retrospective single-center study at MD Anderson Cancer Center

- Study population: 116 adults with dual BCL and TCL diagnosed from separate biopsy specimen (January 2013 – May 2026)

- Exclusion criteria: Composite BCL and TCL in the same biopsy specimen

- Data collection: Demographics, lymphoma subtype, temporal sequence, non-lymphoid malignancies (NLMs), autoimmune comorbidities, family history of hematologic malignancies and viral serologies

 

CONCLUSIONS

- Patient cases with dual BCL/TCL diagnoses are frequently associated with additional malignancies, autoimmune comorbidities, EBV positivity of tumors and family history of malignancy

- These findings support a shared underlying immune dysregulation as predisposing factor in addition to environmental and genetic susceptibilities

- Future genomic and molecular studies are required to explore the underlying mechanisms of dual B-cell and T-cell lymphomagenesis